Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update
Mitazalimab momentum: Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data acce ...
Invitation to Alligator Bioscience’s earnings call on 5 May 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncol ...
Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026
Lund, Sweden – 23 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Shanghai Henlius Biotech, Inc ...
New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026
Lund, Sweden – 20 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Alligator Bioscience provides an update on mitazalimab
Lund, Sweden – 10 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Change in number of shares and votes in Alligator Bioscience AB
During March 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)
The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...